Webinar Series on COVID-19: Jointly organized by Malaysian Society of Infection Control and Infectious Diseases (MyICID) & Institute for Clinical Research, NIH
Speaker: Dr Yasmin Gani, ID Physician, Hospital Sungai Buloh, MOH Malaysia.
More info about the speaker and this webinar available here: https://clinupcovid.mailerpage.com/resources/g7e5g8-medical-management-of-covid-19-an
Just an attempt to promote pharmacy practice in India. It helps for the students and professionals of pharmacy in healthcare, especially Doctor of Pharmacy and Pharmacy Practice students
Webinar Series on COVID-19: Jointly organized by Malaysian Society of Infection Control and Infectious Diseases (MyICID) & Institute for Clinical Research, NIH
Speaker: Dr Yasmin Gani, ID Physician, Hospital Sungai Buloh, MOH Malaysia.
More info about the speaker and this webinar available here: https://clinupcovid.mailerpage.com/resources/g7e5g8-medical-management-of-covid-19-an
Just an attempt to promote pharmacy practice in India. It helps for the students and professionals of pharmacy in healthcare, especially Doctor of Pharmacy and Pharmacy Practice students
Pharmacovigilance is the science of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of medications, biological products, herbalism and traditional medicines.
Video at https://www.youtube.com/watch?v=2rQKMD_5po0
Part of the "Hypoxemia in the Ward Patient with COVID-19" talks in Frederick Southwick's Coursera MOOC on COVID-19, "COVID-19 - A clinical update".
"Dr. Ben Geisler, Hospitalist at Massachusetts General Hospital and Harvard Medical School faculty member reviews the current treatments for COVID-19. He first discusses the management of fluid replacement and diuretics, as well as the indications for bronchodilators and antibiotics. He emphasizes the importance of DVT anticoagulation prophylaxis. He next reviews the potential role of statins, evidence with regards angiotensin converting enzyme inhibitors, and NSAIDS. He next reviews the current indications for the agents of proven efficacy: Remdesivir and Dexamethasone. Finally he discusses the dilemma of equipoise and the best resources for staying up to date with this ever changing topic."
In this iteration, we have added baricitinib and tocilizumab/IL-6 inhibitors.
Chair and Presenters Sumanta Kumar Pal, MD, FASCO, Prof. Laurence Albiges, MD, PhD, and David F. McDermott, MD, prepared useful Practice Aids pertaining to renal cell carcinoma for this CME/MOC/AAPA activity titled “Leveling Up Our RCC Care Strategy: Real-World Translation of Key Evidence Across Treatment Settings.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3LtPuyF. CME/MOC/AAPA credit will be available until December 10, 2024.
Expert Panelists:
Dr. Abiye Kalaiwo, Program Manager, USAID/Nigeria
Dr. Jason Reed, Biomedical HIV Prevention Technical Advisor, Jhpiego
Moderator:
Olawale Durosinmi-Etti, JSI Nigeria
Pharmacovigilance is the science of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of medications, biological products, herbalism and traditional medicines.
Video at https://www.youtube.com/watch?v=2rQKMD_5po0
Part of the "Hypoxemia in the Ward Patient with COVID-19" talks in Frederick Southwick's Coursera MOOC on COVID-19, "COVID-19 - A clinical update".
"Dr. Ben Geisler, Hospitalist at Massachusetts General Hospital and Harvard Medical School faculty member reviews the current treatments for COVID-19. He first discusses the management of fluid replacement and diuretics, as well as the indications for bronchodilators and antibiotics. He emphasizes the importance of DVT anticoagulation prophylaxis. He next reviews the potential role of statins, evidence with regards angiotensin converting enzyme inhibitors, and NSAIDS. He next reviews the current indications for the agents of proven efficacy: Remdesivir and Dexamethasone. Finally he discusses the dilemma of equipoise and the best resources for staying up to date with this ever changing topic."
In this iteration, we have added baricitinib and tocilizumab/IL-6 inhibitors.
Chair and Presenters Sumanta Kumar Pal, MD, FASCO, Prof. Laurence Albiges, MD, PhD, and David F. McDermott, MD, prepared useful Practice Aids pertaining to renal cell carcinoma for this CME/MOC/AAPA activity titled “Leveling Up Our RCC Care Strategy: Real-World Translation of Key Evidence Across Treatment Settings.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3LtPuyF. CME/MOC/AAPA credit will be available until December 10, 2024.
Expert Panelists:
Dr. Abiye Kalaiwo, Program Manager, USAID/Nigeria
Dr. Jason Reed, Biomedical HIV Prevention Technical Advisor, Jhpiego
Moderator:
Olawale Durosinmi-Etti, JSI Nigeria
1. Crohn's and Remicade Infusion Clinics
Health Canada has endorsed Remicade for the treatment of adults with rheumatoid arthritis,
ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and chronic plaque
psoriasis. Patients with Crohns are treated with Remicade when the disease is still active even
though other treatments have been tried. According to Bio Advances treatment guide, Remicade
works by binding to, and neutralizing, TNF-alphas (tumour necrosis factor-alpha), inflammatory
cytokine which are being over produced. Some side effects they list are:
shortness of breath, coughing (upper respiratory infections)
rash, itchiness
headache
urinary tract infections
upset stomach
pain: abdominal, back
dizziness
fatigue
Some of the side effects can be serious and require treatment.
The following are situations where you must not take Remicade:
have a serious infection: sepsis, tuberculosis, abscesses
moderate to severe heart failure
2. allergic to infliximab
history of allergies to mouse proteins
Network Health Group Support System
In my wife's case, the infusion process is coordinated and delivered through the AIM Health Group,
a Managed care plan that integrates the financing and delivery of the Remicade. The infusion arm of
AIM is MedEmerg, which has been delivering innovative healthcare staffing solutions to facilities
across Canada since 1983. Within this structure:
a coordinating nurse in each local area assists with the paperwork and is a liaison with the doctor,
specialty pharmacy , and Health Group
financial support may come from Trillium and the ODB in Ontario: included is a family deductible
based on income tax returns
Remicade will often help with most of the deductible: again based on tax returns
This advice, of course, only applies directly to Ontario residents but could be similar in other
jurisdictions.
Administrative Procedures Crohn's Patient Must Consider
Unfortunately, a patient, as my wife discovered, needs to go through several hoops before receiving
Remicade. And, for a variety of reasons, some the fault of the patient and others of the system,
occasionally it is left too long. In such a case, hopefully, along with surgery, it helps with the
prevention of a reoccurrence, all too common with Crohns. Following are the steps and some notes:
your gastroentomologist needs to seek formal approval: often refused the first time, particularly if
the patient is out of the hospital setting
advised to get a tuberculosis test
contacted by MedEmerg about the infusion appointment
need to open a window with Trillium for payment of Remicade (sometimes in conference call with
Specialty Pharmacy)
if under nursing care with CCAC the ODP pays for the infusions
if over 65 years of age the ODP pays for the infusion
you must obtain letters from your private insurance company when coverage maximum is reached
Clinic Procedures
There is a strict protocol followed in the infusion clinics.
you are first asked how you are. e.g. any sores or open wounds?
3. you are then assigned a recliner: usually 3-6 other people receiving the infusion for the same or
different reasons
your weight is taken: + or 10 lbs; changes affect the units of Remicade required
you are then hooked up to an I.V.: before the administering of the Remicade, any necessary blood
work is sometimes done and a small dose of a steroid is administered
your blood pressure and temperature is periodically checked
the first appointment is usually longer than the normal 2 hours: check for ill effects
a television, videos and snacks are available in the clinic, and clients are welcome to bring in
computers (e.g. may be plug-ins available)
a release sheet is signed at the end and the next appointment given: usually 6-8 weeks
For many, while the infusions are a tie, the result of feeling good and having a life which is enjoyable
far outweighs the need to be infused every 6-8 weeks. My wifes physician has stated that one of the
problems is that patients feel so good they dont get back for regular appointments.
Sources:
hc-sc.gc.ca
med-emerg.com
aimhealthgroup.com
bioadvanvce.ca
Disclaimer: The information contained in this article is for educational purposes only and should not
be used for diagnosis or to guide treatment without the opinion of a health professional. Any reader
who is concerned about his or her health should contact a doctor for advice.
About the author
James Gibson
4. James Gibson is a retired teacher and small business owner. He is a published writer and has a wide
spectrum of interests.
Popular stories
An Introduction to Virtual Particles and Psychic Geography
From the Fashion Runway to the Real Way: TSC Designers
My Favorite Religious Songs: He